Humanised monoclonal antibody therapy for rheumatoid arthritis.
Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than...
Principais autores: | Isaacs, J, Watts, R, Hazleman, B, Hale, G, Keogan, M, Cobbold, S, Waldmann, H |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
1992
|
Registros relacionados
-
HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
por: Isaacs, J, et al.
Publicado em: (1992) -
Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
por: Isaacs, J, et al.
Publicado em: (2004) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
por: Isaacs, J, et al.
Publicado em: (2005) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
por: Isaacs, J, et al.
Publicado em: (2005) -
Humanized monoclonal antibody treatment in rheumatoid arthritis.
por: Kyle, V, et al.
Publicado em: (1991)